1. Home
  2. Live Updates
  3. Ellipses pharma

Live Breaking News & Updates on Ellipses Pharma

Stay updated with breaking news from Ellipses pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC

MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

France General , South Korea , Daiichi Sankyo , Benjamin Besse , Chugai Pharma , Roche Genentech , Saclay University , Aptitude Health , Paris Saclay University , Gustave Roussy Cancer Campus , Ellipses Pharma , Janssen Oncology , Taiho Pharmaceutical , Turning Point Therapeutics , Hanj Y ,

Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following 'Encouraging' Data on Next Generation Selective RET Inhibitor | Illinois

CHICAGO (BUSINESS WIRE) Jun 5, 2023 ....

United States , City Of , United Kingdom , Tobias Arkenau , Christopher Evans , Rajan Jethwa , Biotech Pharmaceutical Co , China National Medicinal Products Administration , Global Head Of Drug Development , American Society Of Clinical Oncology , Ellipses Pharma , Global Head , Drug Development , Kelun Biotech Pharmaceutical , American Society , Clinical Oncology , Sir Christopher Evans , Chief Executive Officer , National Medicinal Products Administration , Greater China , Ellipses Phase , About Ellipses Pharma , Kelun Pharmaceutical , Cell Lung Cancer , Practice Guidelines , Business Wire ,

Pemigatinib Demonstrates Activity in Previously Treated Solid Tumors Harboring Activating FGFR Alterations

Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer. ....

Black Diamond , United States , Israel General , Nuvation Bio , Pemigatinib Pemazyre , Hutchison Medipharma , Yingli Pharma , Chinese University Of Hong Kong , Department Of Investigational Cancer Therapeutics , Foundation Medicine Inc , University Of Texas Md Anderson Cancer Center , Pharma Group , Spectrum Pharmaceuticals , Debiopharm Group , Division Of Cancer Medicine , Hebron Institute Of Oncology , Jordi Rod , Investigational Cancer Therapeutics , Cancer Medicine , Cancer Center , Response Assessment , Foundation Medicine , Ellipses Pharma , Monte Rosa Therapeutics , Oncology One , Sardona Therapeutics ,

BI 907828 Demonstrates Early Efficacy, Safety in MDM2-amplified Dedifferentiated Liposarcoma

The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma. ....

Region Flamande , Patrick Schoffski , Acta Biochim Biophys , University Hospitals Leuven , Boehringer Ingelheim , Rare Cancers Congress , Oncology At Leuven Cancer Institute , Rare Cancers , General Medical Oncology , Leuven Cancer Institute , Sartar Therapeutics , Ellipses Pharma , Merck Healthcare , Biochim Biophys Sin , Sarcomas Tgct , 2023 Esmo Sarcoma And Rare Cancers Congress , Dedifferentiated Liposarcoma ,

LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors

LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City Of , United Kingdom , Lucy Shaw , James Field , Victor Greiff , Hendrik Tobias Arkenau , University College London , Sarah Cannon Research Institute , University Of Oslo , Prof Hendrik Tobias Arkenau , Prof Victor Greiff , Business Wire , Prof Arkenau , Chief Medical Officer , Global Head , Drug Development , Ellipses Pharma , Consultant Medical Oncologist , University College , Executive Medical Director , Associate Professor ,